Continuous Liposome Manufacturing via Concentric Injection Mixing
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current liposome manufacturing processes are inefficient and prone to variations due to changes in processing conditions and human intervention, leading to inconsistencies in product quality and increased regulatory burdens, while also being time-consuming and costly.
Innovation Solution
A continuous manufacturing system for liposomes that includes a mixer, a vessel, and injection ports with concentric conduits for precise mixing of lipid and aqueous solutions, reducing human intervention and allowing for real-time quality control through process analytical technology (PAT), thereby ensuring consistent product quality and scalability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If continuous manufacturing system is implemented, then productivity and consistency are improved, but device complexity increases
Solution Approach 1:
The continuous manufacturing system is divided into distinct functional modules: a mixer for combining lipid and aqueous solutions, injection ports for precise solution delivery, and a vessel for liposome formation. Each module performs a specific function, allowing the complex manufacturing process to be managed through modular components that can be independently optimized and maintained.
Solution Approach 2:
The system implements continuous manufacturing by maintaining constant flow of lipid solution through the mixer and injection ports, eliminating batch processing interruptions. The concentric conduit design enables continuous mixing and formation of liposomes, significantly improving productivity compared to traditional batch methods while maintaining consistent product quality through uninterrupted production.
2Manufacturing precision
If concentric conduit injection ports are used, then manufacturing precision is improved, but device complexity increases
Solution Approach 1:
The injection port features a concentric conduit design where an inner conduit is nested within an outer conduit. The inner conduit delivers lipid solution while the outer conduit delivers aqueous solution, allowing precise control of solution mixing ratios and flow rates. This nested structure enables high manufacturing precision for liposome formulation consistency.
Solution Approach 2:
The concentric conduit structure acts as an intermediary mixing chamber where lipid and aqueous solutions are precisely combined before liposome formation. The controlled interaction between the two solutions through the concentric design ensures consistent formulation, serving as a mediator that translates input solutions into uniform liposome products.
3Manufacturing precision
If closed-environment manufacturing is implemented, then product purity is improved, but loss of time in setup and validation increases
Solution Approach 1:
The system operates in a closed environment that protects the liposome manufacturing process from external contamination. This controlled environment maintains product purity by preventing particulate and microbial contamination during the continuous manufacturing process, ensuring consistent product quality while meeting regulatory requirements.
Solution Approach 2:
The continuous manufacturing process eliminates the need for repeated batch setup and validation by maintaining uninterrupted production. Once the closed system is established and validated, it can continuously produce liposomes with consistent quality attributes, significantly reducing the time loss associated with repeated batch processing validation while maintaining high product purity standards.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The system significantly reduces waste, processing time, and manufacturing costs, while ensuring consistent product quality and regulatory compliance by minimizing variations and allowing for faster drug delivery.
Implementation Method 1
providing the organic solvent-lipid solution to a first inlet of an injection port... providing an aqueous solution to a second inlet of the injection port... mixing the organic lipid solution and the aqueous solution to create a plurality of liposomes
Implementation Method 2
mixing the organic lipid solution and the aqueous solution to create a plurality of liposomes
Data Source
AI summary
The present disclosure provides systems and methods for the continuous production of liposomes. An example method includes (a) mixing a solution of lipid and organic solvent from one or more containers to create an organic solvent-lipid solution, (b) providing the organic solvent-lipid solution to a first inlet of an injection port at a first flow rate, wherein the first inlet is in fluid communication with a first conduit, (c) providing an aqueous solution to a second inlet of the injection port at a second flow rate, wherein the second inlet is influid communication with a second conduit, wherein the first conduit is positioned concentrically within the second conduit at an outlet of the injection port, and wherein the first conduit extends through the outlet of the injection port, and (d) mixing the organic lipid solution and the aqueous solution to create a plurality of liposomes.